GlassScriptPhysician profile
Marna Moore-Barr
NPI 1013395821
$5,626.48
in general payments reported to CMS, 2019-2025
20 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $889 · 2022: $891 · 2023: $1,085 · 2024: $1,061 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.33 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,517.31 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $561.70 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $554.95 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $503.97 | 2021-2025 | Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $445.37 | 2023-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $394.00 | 2021-2025 | Fasenra, Tezspire |
| Csl Behring | $293.12 | 2021-2025 | Haegarda, Andembry, Hizentra |
| Grifols USA, LLC | $221.73 | 2021-2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.37 | 2021-2024 | Spiriva Respimat, Stiolto Respimat |
| Incyte Corporation | $183.53 | 2022-2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $170.29 | 2023-2025 | |
| Amgen INC. | $120.46 | 2021-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $117.38 | 2025 | Neffy |
| Genentech USA, INC. | $81.49 | 2021-2025 | Xolair |
| Alk-Abello, INC | $76.86 | 2021-2025 | Grastek, Odactra, Ragwitek |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $56.69 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $43.22 | 2025 | Ruconest |
| Kaleo, INC. | $42.09 | 2021-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $30.05 | 2023 | |
| Cycle Pharmaceuticals INC | $21.90 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marna Moore-Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.